We were delighted to talk with Dr. Michael S. Blaiss (Medical College of Georgia, Augusta University, Augusta, GA, USA) to discuss chronic cough and the latest advances to look out for in 2022.
The abstract ‘Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals With Refractory Or Unexplained Chronic Cough Enrolled In Phase 3 Trials Of Gefapixant‘ was presented at AAAAI 2022, 25-28 February.
Questions
- What are the definitions of refractory chronic cough and unexplained chronic cough? (0:20)
- What is the latest research you are looking forward to exploring in chronic cough during 2022? (1:27)
Disclosures: Michael Blaiss discloses consulting for Merck and Bellus, serving on advisory boards for Merck and Bellus, and participating in Speaker’s Bureaus for Merck.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAAAI meeting 2022.
